SWTX Aug 2024 30.000 call
| Previous Close | 9.44 |
| Open | 9.52 |
| Bid | 7.40 |
| Ask | 12.00 |
| Strike | 30.00 |
| Expire Date | 2024-08-16 |
| Day's Range | 9.44 - 9.52 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 4 |
GlobeNewswireSpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, for the treatment of pediatric and adult patients with neurofibromatosis type 1- associated plexiform neurofibromas (NF1
GuruFocus.comInsider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
On June 3, 2024, Julie Hambleton, Director at SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 4,648 shares of the company.
GuruFocus.comInsider Sale: COO Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX)
Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 20,000 shares of the company on June 3, 2024, according to a recent SEC filing.
